Angiogenesis in hematologic malignancies
- 19 February 2003
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 45 (3) , 227-244
- https://doi.org/10.1016/s1040-8428(02)00135-x
Abstract
No abstract availableKeywords
This publication has 159 references indexed in Scilit:
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- SOLUBLE IL-6Rα UPREGULATES IL-6, MMP-1 AND MMP-2 SECRETION IN BONE MARROW STROMAL CELLSCytokine, 2000
- The Hallmarks of CancerCell, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast CancerNew England Journal of Medicine, 1988
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971